Navigation Links
William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
Date:6/18/2008

ialize peramivir in Japan. For more information about BioCryst, please visit the Company's web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not recei
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Gen-Probe to Webcast Presentation at the William Blair & Company 28th Annual Growth Stock Conference
2. Alexion to Present at the William Blair 28th Annual Growth Stock Conference
3. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
4. Zimmer Holdings to Present at William Blair Growth Stock Conference
5. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
6. NxStage Medical to Present at William Blair Growth Stock Conference
7. Kendle Appoints Patricia Williams Vice President, Commercial Operations
8. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
9. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
10. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
11. Amarin Appoints Dr. William Mason as Lead Independent Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... Join us for a webinar at 12 pm ... using the Transcreener® ADP Assay , Register Now ... being incorporated into lead development efforts because longer engagement ... therapeutic window and reduced side effects. Though residence ... surface plasmon resonance, conjugation of drugs can affect their ...
(Date:4/24/2015)... , April 24, 2015 /PRNewswire/ - BioAmber Inc. ... Bayer MaterialScience as the supplier of bio-succinic acid ... bio-based polyurethanes for textile applications that Bayer MaterialScience ... has launched IMPRANIL ® eco, a series ... that reaches as high as 65%.  IMPRANIL ® ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of ... the lighting market. In recent months, there ... in emerging markets such as Russia, South America, ... applications such as streetlight and area lighting, tunnel ... launched in 2005 the Acrich technology from Seoul ...
(Date:4/23/2015)... Fla. , April 23, 2015 BioTE ... releases his book "Age Healthier Live Happier - Avoiding ... off the Age Management Medicine Group Conference at JW ... 26, 2015. ",Age Healthier Live Happier, is ... to avoid over-medication and searching for a higher quality ...
Breaking Biology Technology:BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3
... DIEGO, Aug. 13 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ... Institutional,Shareholder Services (ISS), two leading proxy advisory firms, have,recommended ... Eli,Lilly and Company (NYSE: LLY ) at the ... for August 20, 2008., The Board of Directors ...
... for Hepatitis B, as well as HIV-1 ... -, SAN DIEGO, Aug. 13 Gen-Probe Incorporated,(Nasdaq: ... and Drug Administration,(FDA) has approved its supplemental regulatory application ... for the hepatitis B,virus (HBV). The FDA had previously ...
... 13 Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assignee of ... creditors, announced today that all pharmaceutical,intellectual property will be ... One of the pieces of intellectual property for ... a branded drug that currently has,more than $2 billion ...
Cached Biology Technology:SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 2SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 3SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 4FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group issues ... (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one of ... on their experience with the Wocket in multiple scenarios and ... Whole Foods and other retailers, making both debit and credit ... also says, "If the company meets their plans in ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Madrid, August 16, 2010.- Over 1.500 breast pathology experts will ... 16th World Congress of the Senologic International Society (SIS). This ... Senology and Breast Diseases (SESPM) will take place in the ... According to Dr. Carlos Vzquez, president of the SIS and ...
... Clinical trials using patients, own immune cells to target tumors ... if the patients also receive large doses of drugs designed ... life-threatening side effects. Now a team of MIT engineers ... smuggling them on the backs of the cells sent in ...
... rapid and less expensive DNA sequencing strategy, scientists have ... Kabuki syndrome, a rare disorder that causes multiple birth ... human genome, the new approach sequences just the exome, ... protein-coding genes. Kabuki syndrome, which has an ...
Cached Biology News:1,500 worldwide experts debate the latest advances in breast pathologies' treatments in Valencia 2Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells 2Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells 3Discovered gene causes Kabuki syndrome 2Discovered gene causes Kabuki syndrome 3
PKC (pSer345), phospho-specific...
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
... 100 g monoclonal antibody which can ... V from heart mitochondria. Also included are ... control immunocapture. The Complex V immunocapture kit ... (E.C. 3.6.3.14) from small amounts of tissue. ...
Biology Products: